An assessment by the Statin Intolerance Panel: 2014 update
Abstract This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical lipidology 2014-05, Vol.8 (3), p.S72-S81 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S81 |
|---|---|
| container_issue | 3 |
| container_start_page | S72 |
| container_title | Journal of clinical lipidology |
| container_volume | 8 |
| creator | Guyton, John R., MD, FNLA Bays, Harold E., MD, FNLA Grundy, Scott M., MD, PhD, FNLA Jacobson, Terry A., MD, FACP, FNLA |
| description | Abstract This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design. |
| doi_str_mv | 10.1016/j.jacl.2014.03.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1521328446</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1933287414001585</els_id><sourcerecordid>1521328446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-be37d62e8af86d233aebe7a4a048d537a97bdbc00589b7ecf5b0fae62cdc479b3</originalsourceid><addsrcrecordid>eNp9kUtr3TAQhUVpaF79A1kUL7uxo6clh1IIoXlAIIGka6HHmMj1tW8luXD_fWRu2kUXWWkW5xyd-QahM4Ibgkl7PjSDcWNDMeENZg3G9AM6Ikq2NZeq-1jmjrGaKskP0XFKA8ZCSCw-oUPKZcc450fo4nKqTEqQ0gamXNldlV-gesomh6m6m_I8QjSTg-rRTDBeVOtn1bL1JsMpOujNmODz23uCfl7_eL66re8fbu6uLu9rx4XItQUmfUtBmV61njJmwII03GCuvGDSdNJ660o51VkJrhcW9wZa6rwrNS07QV_3uds4_14gZb0JycE4lkbzkjQRlDCqOG-LlO6lLs4pRej1NoaNiTtNsF6Z6UGvzPS6hsZMF2bF9OUtf7Eb8P8sfyEVwbe9AMqWfwJEnVyAAsWHCC5rP4f387__Z3djmIIz4y_YQRrmJU6FnyY6UY3103q19WiEY0yEEuwVSI-Q5A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1521328446</pqid></control><display><type>article</type><title>An assessment by the Statin Intolerance Panel: 2014 update</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Guyton, John R., MD, FNLA ; Bays, Harold E., MD, FNLA ; Grundy, Scott M., MD, PhD, FNLA ; Jacobson, Terry A., MD, FACP, FNLA</creator><creatorcontrib>Guyton, John R., MD, FNLA ; Bays, Harold E., MD, FNLA ; Grundy, Scott M., MD, PhD, FNLA ; Jacobson, Terry A., MD, FACP, FNLA</creatorcontrib><description>Abstract This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design.</description><identifier>ISSN: 1933-2874</identifier><identifier>EISSN: 1876-4789</identifier><identifier>DOI: 10.1016/j.jacl.2014.03.002</identifier><identifier>PMID: 24793444</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cardiovascular ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - prevention & control ; Clinical Trials as Topic ; Drug intolerance ; Drug Tolerance ; Evidence-Based Medicine ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Patient-centered medicine ; Risk Factors ; Statin adverse effects ; Statin safety ; Statins</subject><ispartof>Journal of clinical lipidology, 2014-05, Vol.8 (3), p.S72-S81</ispartof><rights>National Lipid Association</rights><rights>2014 National Lipid Association</rights><rights>Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-be37d62e8af86d233aebe7a4a048d537a97bdbc00589b7ecf5b0fae62cdc479b3</citedby><cites>FETCH-LOGICAL-c455t-be37d62e8af86d233aebe7a4a048d537a97bdbc00589b7ecf5b0fae62cdc479b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jacl.2014.03.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24793444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guyton, John R., MD, FNLA</creatorcontrib><creatorcontrib>Bays, Harold E., MD, FNLA</creatorcontrib><creatorcontrib>Grundy, Scott M., MD, PhD, FNLA</creatorcontrib><creatorcontrib>Jacobson, Terry A., MD, FACP, FNLA</creatorcontrib><title>An assessment by the Statin Intolerance Panel: 2014 update</title><title>Journal of clinical lipidology</title><addtitle>J Clin Lipidol</addtitle><description>Abstract This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design.</description><subject>Cardiovascular</subject><subject>Cardiovascular Diseases - complications</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Clinical Trials as Topic</subject><subject>Drug intolerance</subject><subject>Drug Tolerance</subject><subject>Evidence-Based Medicine</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Patient-centered medicine</subject><subject>Risk Factors</subject><subject>Statin adverse effects</subject><subject>Statin safety</subject><subject>Statins</subject><issn>1933-2874</issn><issn>1876-4789</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtr3TAQhUVpaF79A1kUL7uxo6clh1IIoXlAIIGka6HHmMj1tW8luXD_fWRu2kUXWWkW5xyd-QahM4Ibgkl7PjSDcWNDMeENZg3G9AM6Ikq2NZeq-1jmjrGaKskP0XFKA8ZCSCw-oUPKZcc450fo4nKqTEqQ0gamXNldlV-gesomh6m6m_I8QjSTg-rRTDBeVOtn1bL1JsMpOujNmODz23uCfl7_eL66re8fbu6uLu9rx4XItQUmfUtBmV61njJmwII03GCuvGDSdNJ660o51VkJrhcW9wZa6rwrNS07QV_3uds4_14gZb0JycE4lkbzkjQRlDCqOG-LlO6lLs4pRej1NoaNiTtNsF6Z6UGvzPS6hsZMF2bF9OUtf7Eb8P8sfyEVwbe9AMqWfwJEnVyAAsWHCC5rP4f387__Z3djmIIz4y_YQRrmJU6FnyY6UY3103q19WiEY0yEEuwVSI-Q5A</recordid><startdate>201405</startdate><enddate>201405</enddate><creator>Guyton, John R., MD, FNLA</creator><creator>Bays, Harold E., MD, FNLA</creator><creator>Grundy, Scott M., MD, PhD, FNLA</creator><creator>Jacobson, Terry A., MD, FACP, FNLA</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201405</creationdate><title>An assessment by the Statin Intolerance Panel: 2014 update</title><author>Guyton, John R., MD, FNLA ; Bays, Harold E., MD, FNLA ; Grundy, Scott M., MD, PhD, FNLA ; Jacobson, Terry A., MD, FACP, FNLA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-be37d62e8af86d233aebe7a4a048d537a97bdbc00589b7ecf5b0fae62cdc479b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Cardiovascular</topic><topic>Cardiovascular Diseases - complications</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Clinical Trials as Topic</topic><topic>Drug intolerance</topic><topic>Drug Tolerance</topic><topic>Evidence-Based Medicine</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Patient-centered medicine</topic><topic>Risk Factors</topic><topic>Statin adverse effects</topic><topic>Statin safety</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guyton, John R., MD, FNLA</creatorcontrib><creatorcontrib>Bays, Harold E., MD, FNLA</creatorcontrib><creatorcontrib>Grundy, Scott M., MD, PhD, FNLA</creatorcontrib><creatorcontrib>Jacobson, Terry A., MD, FACP, FNLA</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical lipidology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guyton, John R., MD, FNLA</au><au>Bays, Harold E., MD, FNLA</au><au>Grundy, Scott M., MD, PhD, FNLA</au><au>Jacobson, Terry A., MD, FACP, FNLA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An assessment by the Statin Intolerance Panel: 2014 update</atitle><jtitle>Journal of clinical lipidology</jtitle><addtitle>J Clin Lipidol</addtitle><date>2014-05</date><risdate>2014</risdate><volume>8</volume><issue>3</issue><spage>S72</spage><epage>S81</epage><pages>S72-S81</pages><issn>1933-2874</issn><eissn>1876-4789</eissn><abstract>Abstract This article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24793444</pmid><doi>10.1016/j.jacl.2014.03.002</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1933-2874 |
| ispartof | Journal of clinical lipidology, 2014-05, Vol.8 (3), p.S72-S81 |
| issn | 1933-2874 1876-4789 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1521328446 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Cardiovascular Cardiovascular Diseases - complications Cardiovascular Diseases - drug therapy Cardiovascular Diseases - prevention & control Clinical Trials as Topic Drug intolerance Drug Tolerance Evidence-Based Medicine Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Patient-centered medicine Risk Factors Statin adverse effects Statin safety Statins |
| title | An assessment by the Statin Intolerance Panel: 2014 update |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T16%3A17%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20assessment%20by%20the%20Statin%20Intolerance%20Panel:%202014%20update&rft.jtitle=Journal%20of%20clinical%20lipidology&rft.au=Guyton,%20John%20R.,%20MD,%20FNLA&rft.date=2014-05&rft.volume=8&rft.issue=3&rft.spage=S72&rft.epage=S81&rft.pages=S72-S81&rft.issn=1933-2874&rft.eissn=1876-4789&rft_id=info:doi/10.1016/j.jacl.2014.03.002&rft_dat=%3Cproquest_cross%3E1521328446%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1521328446&rft_id=info:pmid/24793444&rft_els_id=1_s2_0_S1933287414001585&rfr_iscdi=true |